TransCode Therapeutics Inc Stock

$2.37

5.95% today

Nasdaq, Feb 28, 04:52 pm CET

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

TransCode Therapeutics Inc Stock price

$2.52

-105,597.48 100.00% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.83 24.78%

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$1.75m
Enterprise Value	$20.00k
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.80
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-14.63m
Free Cash Flow (TTM) Free Cash Flow	$-15.87m
Cash position	$1.88m
EPS (TTM) EPS	$-265.83
P/S forward	5.83
EV/Sales forward	0.07
Short interest	52.90%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

TransCode Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast TransCode Therapeutics Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast TransCode Therapeutics Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from TransCode Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.55 0.55	34% 34% -
Gross Profit	-0.55 -0.55	34% 34% -
- Selling and Administrative Expenses	4.14 4.14	51% 51% -
- Research and Development Expense	9.38 9.38	19% 19% -
EBITDA	-14 -14	31% 31% -
- Depreciation and Amortization	0.55 0.55	34% 34% -
EBIT (Operating Income) EBIT	-15 -15	30% 30% -
Net Profit	-15 -15	24% 24% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

TransCode Therapeutics Inc Stock News

Neutral

PRNewsWire

●

3 days ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

BOSTON , Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today held the adjourned session of its Special Meeting from February 4, 2025, (the "Special Meeting"). Shareholders voted upon the two proposals outlined below and described in the Com...

Neutral

PRNewsWire

●

22 days ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON , Feb. 6, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three pa...

Neutral

PRNewsWire

●

24 days ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

BOSTON , Feb. 4, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on February 4, 2025 (the "Special Meeting") has been adjourned until February 25, 2025 at 9:30 a.m. Eastern time (the "Adjou...

More TransCode Therapeutics Inc News

Company Profile

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Head office	United States
CEO	Thomas Fitzgerald
Employees	10
Founded	2016
Website	www.transcodetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now